Format

Send to

Choose Destination
Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Author information

1
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. acastellino@cittadellasalute.to.it.
2
Mayo Clinic, Rochester, MN, USA. acastellino@cittadellasalute.to.it.
3
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
4
Mayo Clinic, Rochester, MN, USA.
5
Department of translational Medicine, University of Eastern Piedmont, Novara, Italy.
6
Cornell University, New York, NY, USA.
7
Mayo Clinic, Scottsdale, AZ, USA.
8
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
9
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
10
Mayo Clinic, Jacksonville, FL, USA.
11
Unit of Hematology and Hemopoietic Stem Cell Transplantation, Ospedale Cardinale G Panico, Tricase, Italy.
12
Division of Medical Oncology, Centro di Riferimento Oncologico Aviano National Cancer Institute, Aviano, Italy.
13
Department of Oncology and Hematology, Infermi Hospital, Rimini, Italy.
14
Unit of Clinical Epidemiology, CPO, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.

Abstract

Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials, conducted by Mayo Clinic (MC) and Fondazione Italiana Linfomi (FIL). All patients received R-CHOP21 plus lenalidomide. Long-term progression-free survival (PFS), time to progression (TTP), overall survival (OS) and late toxicities and second tumors were analyzed. Hundred and twelve patients (63 MC, 49 FIL) were included. Median age was 69 years, 88% were stage III-IV. At a median follow-up of 5.1 years, 5y-PFS was 63.5%, 5y-TTP 70.1% and 5y-OS 75.4%; according to cell of origin (COO): 5y-PFS 52.8% vs 64.5%, 5y-TTP 61.6% vs 69.6% and 5y-OS 68.6% vs 74.1% in germinal center (GCB) vs non-GCB respectively. Four patients experienced grade 4-5 late toxicities. Grade ≤ 3 toxicities were infections (N = 4), thrombosis (N = 1) and neuropathy (N = 3). Seven seconds tumors were observed. Long-term follow-up demonstrates that R2-CHOP21 efficacy was maintained with high rates of PFS, TTP, and OS. Lenalidomide appears to mitigate the negative prognosis of non-GCB phenotype. Incidence of therapy-related secondary malignancies and late toxicities were low.

PMID:
30410035
PMCID:
PMC6224549
DOI:
10.1038/s41408-018-0145-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center